摘要
卵巢上皮性癌病死率高居妇科常见恶性肿瘤首位,铂耐药复发是棘手的临床问题。铂耐药复发卵巢癌患者非铂单药化疗有效率仅10%~20%。化疗联合抗血管药物、PARP抑制剂、免疫检查点抑制剂等在铂耐药复发卵巢癌领域开展了诸多研究,给我们带来了新的选择。但是仍存在总体有效率不高、缺乏预测疗效的有效标志物等问题。
The case fatality rate of epithelial ovarian cancer is the highest among gynecological malignancies.Platinum resistance is a key clinical problem difficult to deal with.The efficacy of non-platinum chemotherapy is only 10%-20%.There have been many clinical trials about chemotherapy combined with anti-vascular agents,PARP inhibitors or immunecheckpoint inhibitors in platinum-resistant recurrent ovarian cancer,which have brought us new choices.However,there are still some problems,such as the low overall response rate and the lack of effective markersfor efficacy prediction.
作者
李一帆
李宁
吴令英
LI Yi-fan;LI Ning;WU Ling-ying(National Cancer Canter/National Clinical Research Canter for Cancer/Cancer Hospital,Chinese Academy of Medical Sciences and Peking Union Medical College,Beijing 100021,China)
出处
《中国实用妇科与产科杂志》
CAS
CSCD
北大核心
2022年第5期503-507,共5页
Chinese Journal of Practical Gynecology and Obstetrics
基金
国家重点研发计划重大慢性非传染性疾病防控研究(2016YFC1303700)
。
关键词
卵巢上皮性癌
复发
铂耐药
治疗
epithelial ovarian cancer
recurrence
platinum resistance
treatment
